Drug Type Small molecule drug |
Synonyms OBT-893, SH-BC-893 |
Target |
Mechanism PP2A stimulants(Protein phosphatase 2A stimulants), S1PRs agonists(Sphingosine 1-phosphate receptor agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Breast Cancer | Preclinical | US | Obsidian Therapeutics, Inc.Startup | - |
Castration-Resistant Prostatic Cancer | Preclinical | US | Obsidian Therapeutics, Inc.Startup | - |
Colorectal Cancer | Preclinical | US | Obsidian Therapeutics, Inc.Startup | - |
Pancreatic Cancer | Preclinical | US | Obsidian Therapeutics, Inc.Startup | - |